LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Your last searches

  1. AU="Hensel, Elizabeth"
  2. AU="Guerini, Fabio"

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Safety and immunogenicity of a single dose of Tdap compared to Td in pregnant women in Mali and 3 its effect on infant immune responses: a single-centre, randomised, double-blind, active-controlled phase 2 study.

    Haidara, Fadima Cheick / Tapia, Milagritos D / Diallo, Fatoumata / Portillo, Susana / Williams, Margaret / Traoré, Awa / Rotrosen, Elizabeth / Hensel, Elizabeth / Makowski, Mat / Selamawi, Semhal / Powell, Jonathan A / Kotloff, Karen L / Pasetti, Marcela F / Sow, Samba O / Neuzil, Kathleen M

    EClinicalMedicine

    2024  Volume 71, Page(s) 102556

    Abstract: Background: While maternal pertussis vaccination is a strategy to reduce infant morbidity, safety and immunogenicity data are limited in sub-Saharan Africa. We aimed to evaluate the safety of a single dose of tetanus, diphtheria and acellular pertussis ... ...

    Abstract Background: While maternal pertussis vaccination is a strategy to reduce infant morbidity, safety and immunogenicity data are limited in sub-Saharan Africa. We aimed to evaluate the safety of a single dose of tetanus, diphtheria and acellular pertussis vaccine (Tdap) vaccine compared to tetanus and diphtheria vaccine (Td) vaccine in pregnant women in Bamako, Mali and to assess the pertussis toxin (PT) antibody response at birth.
    Methods: In this phase 2, single-centre, randomised, double-blind, active-controlled study, from 23 January 2019 to 10 July 2019, healthy 18-39 year old women in the second trimester of a singleton pregnancy were randomised 2:1 to receive Tdap or Td. Blood was tested for serum immunoglobulin G (IgG) against PT and other vaccine antigens using a qualified Meso Scale Discovery multiplex immunoassay. The co-primary objectives evaluated safety and birth anti-PT levels. Infant immune responses to whole-cell pertussis vaccine (DTwP) were assessed. Statistical analysis was descriptive. This trial is registered with clinicaltrials.gov, NCT03589768.
    Findings: 133 women received Tdap and 67 received Td, with 126 and 66 livebirths, respectively. In the Tdap group, 22 serious adverse events (SAEs) including one maternal death occurred in 20 participants (15·0%), with 10 SAEs in 10 participants (14·9%) in the Td group. Among infants, 18 events occurred among 13 participants (10.3%) and 8 SAEs in 6 participants (9.1%), including three and two infant deaths, occurred in Tdap and Td groups, respectively. None were related to study vaccines. Anti-PT geometric mean concentration (GMC) at birth in the Tdap group was higher than in the Td group (55.4 [46.2-66.6] IU/ml vs 7.9 [5.4-11.5] IU/ml). One month after the third dose of DTwP, the GMC in infants born to mothers in the Tdap group were lower compared to the Td group (20.2 [13.7-29.9] IU/ml vs 77.2 [32.2-184.8] IU/ml). By 6 months of age, the anti- PT GMCs were 17.3 [12.8-23.4] IU/ml and 67.1 [35.5-126.7] IU/ml in Tdap and Td groups, respectively. At birth, anti-tetanus toxin (TT) GMCs were higher in infants in the Td vs Tdap group (5.9 [5.0-7.0] IU/ml vs 4.1 [3.5-4.8] IU/ml). Anti-diphtheria toxin GMCs were similar in both groups.
    Interpretation: Tdap administered to pregnant women in Mali is safe and well-tolerated. Infants of mothers who received Tdap were born with high PT and protective anti-TT antibody levels. By six months of age, after primary vaccination, the PT levels were lower in the Tdap group compared to the Td group. The blunted immune responses to primary DTwP vaccination in the Tdap infant group warrant further study.
    Funding: This project was funded by National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), under contract numbers 75N93021C00012 (The Emmes Company), and HHSN27220130000221 (University of Maryland, Baltimore). Dr. Susana Portillo was supported by NIH award no. T32AI007524. NIAID, NIH provided Tdap vaccine (BOOSTRIX).
    Language English
    Publishing date 2024-03-28
    Publishing country England
    Document type Journal Article
    ISSN 2589-5370
    ISSN (online) 2589-5370
    DOI 10.1016/j.eclinm.2024.102556
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Safety and Immunogenicity of an Andes Virus DNA Vaccine by Needle-Free Injection: A Randomized, Controlled Phase 1 Study.

    Paulsen, Grant C / Frenck, Robert / Tomashek, Kay M / Alarcon, Rodolfo M / Hensel, Elizabeth / Lowe, Ashley / Brocato, Rebecca L / Kwilas, Steve A / Josleyn, Matthew D / Hooper, Jay W

    The Journal of infectious diseases

    2023  Volume 229, Issue 1, Page(s) 30–38

    Abstract: Background: Andes virus (ANDV), a rodent-borne hantavirus, causes hantavirus pulmonary syndrome (HPS). The safety and immunogenicity of a novel ANDV DNA vaccine was evaluated.: Methods: Phase 1, double-blind, dose-escalation trial randomly assigned ... ...

    Abstract Background: Andes virus (ANDV), a rodent-borne hantavirus, causes hantavirus pulmonary syndrome (HPS). The safety and immunogenicity of a novel ANDV DNA vaccine was evaluated.
    Methods: Phase 1, double-blind, dose-escalation trial randomly assigned 48 healthy adults to placebo or ANDV DNA vaccine delivered via needle-free jet injection. Cohorts 1 and 2 received 2 mg of DNA or placebo in a 3-dose (days 1, 29, 169) or 4-dose (days 1, 29, 57, 169) schedule, respectively. Cohorts 3 and 4 received 4 mg of DNA or placebo in the 3-dose and 4-dose schedule, respectively. Subjects were monitored for safety and neutralizing antibodies by pseudovirion neutralization assay (PsVNA50) and plaque reduction neutralization test (PRNT50).
    Results: While 98% and 65% of subjects had at least 1 local or systemic solicited adverse event (AE), respectively, most AEs were mild or moderate; no related serious AEs were detected. Cohorts 2, 3, and 4 had higher seroconversion rates than cohort 1 and seropositivity of at least 80% by day 197, sustained through day 337. PsVNA50 geometric mean titers were highest for cohort 4 on and after day 197.
    Conclusions: This first-in-human candidate HPS vaccine trial demonstrated that an ANDV DNA vaccine was safe and induced a robust, durable immune response. Clinical Trials Registration. NCT03682107.
    MeSH term(s) Adult ; Humans ; Orthohantavirus ; Vaccines, DNA/adverse effects ; Antibodies, Neutralizing ; Hantavirus Pulmonary Syndrome ; DNA ; Immunogenicity, Vaccine ; Double-Blind Method ; Antibodies, Viral
    Chemical Substances Vaccines, DNA ; Antibodies, Neutralizing ; DNA (9007-49-2) ; Antibodies, Viral
    Language English
    Publishing date 2023-06-28
    Publishing country United States
    Document type Randomized Controlled Trial ; Clinical Trial, Phase I ; Journal Article
    ZDB-ID 3019-3
    ISSN 1537-6613 ; 0022-1899
    ISSN (online) 1537-6613
    ISSN 0022-1899
    DOI 10.1093/infdis/jiad235
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Safety and immunogenicity of live, attenuated intranasal Bordetella pertussis vaccine (BPZE1) in healthy adults.

    Buddy Creech, C / Jimenez-Truque, Natalia / Kown, Naomi / Sokolow, Katherine / Brady, Eric J / Yoder, Sandra / Solovay, Ken / Rubin, Keith / Noviello, Stephanie / Hensel, Elizabeth / Selamawi, Semhal / Bakare, Adetunji / Makowski, Mat / Lu, Kristina

    Vaccine

    2022  Volume 40, Issue 47, Page(s) 6740–6746

    Abstract: Background: BPZE1 is a live, attenuated pertussis vaccine derived from B. pertussis strain Tohama I modified by genetic removal or inactivation of 3 B. pertussis toxins: pertussis toxin, dermonecrotic toxin, and tracheal cytotoxin. This Phase 2a study ... ...

    Abstract Background: BPZE1 is a live, attenuated pertussis vaccine derived from B. pertussis strain Tohama I modified by genetic removal or inactivation of 3 B. pertussis toxins: pertussis toxin, dermonecrotic toxin, and tracheal cytotoxin. This Phase 2a study evaluated the safety and immunogenicity of liquid or lyophilized BPZE1 vaccine administered intranasally by needleless tuberculin syringe or mucosal atomization device (VaxINator
    Methods: Fifty healthy male and non-pregnant female participants 18-49 years of age were enrolled. Participants were randomized 3:3:3:1 to a single lyophilized dose of 10
    Results: Across all groups, 35/50 (70 %) experienced at least one local adverse event (AE) and 31/50 (62 %) experienced at least one systemic AE, with similar AE frequencies observed between the highest 10
    Discussion: Lyophilized BPZE1 vaccine was well tolerated and immunogenic at the highest dose (10
    MeSH term(s) Adult ; Male ; Female ; Humans ; Pertussis Vaccine/adverse effects ; Bordetella pertussis ; Whooping Cough/prevention & control ; Tuberculin ; Administration, Intranasal ; Vaccines, Attenuated ; Immunogenicity, Vaccine
    Chemical Substances Pertussis Vaccine ; Tuberculin ; Vaccines, Attenuated
    Language English
    Publishing date 2022-10-08
    Publishing country Netherlands
    Document type Randomized Controlled Trial ; Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 605674-x
    ISSN 1873-2518 ; 0264-410X
    ISSN (online) 1873-2518
    ISSN 0264-410X
    DOI 10.1016/j.vaccine.2022.09.075
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Factors affecting the likelihood that people with intellectual disabilities will gain employment.

    Rose, John / Saunders, Katie / Hensel, Elizabeth / Kroese, Biza Stenfert

    Journal of intellectual disabilities : JOID

    2005  Volume 9, Issue 1, Page(s) 9–23

    Abstract: The study aimed to identify factors that may affect the likelihood that people with intellectual disabilities will find employment through a supported employment agency. A retrospective analysis of the files of the last 200 individuals to use such an ... ...

    Abstract The study aimed to identify factors that may affect the likelihood that people with intellectual disabilities will find employment through a supported employment agency. A retrospective analysis of the files of the last 200 individuals to use such an agency was carried out. Variables were identified that may influence outcome, such as demographic factors, job preferences and identified support needs. A specific rating of staff assessed client motivation was developed from written comments made by staff. Staff assessed motivation after two weeks on the scheme was found to be the only significant predictor of employment outcome. Motivation levels decreased for all groups of participants while at the agency, irrespective of work outcome. This study highlights that a greater emphasis on motivation within employment agencies may increase the chances of people with intellectual disability finding work.
    MeSH term(s) Adult ; Employment, Supported ; Environment ; Female ; Forecasting ; Humans ; Intellectual Disability/psychology ; Male ; Motivation ; Psychology
    Language English
    Publishing date 2005-03
    Publishing country England
    Document type Journal Article
    ZDB-ID 2071898-6
    ISSN 1744-6309 ; 1744-6295 ; 1469-0047
    ISSN (online) 1744-6309
    ISSN 1744-6295 ; 1469-0047
    DOI 10.1177/1744629505049725
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top